Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02696798 · ClinicalTrials.gov registry record · Phase 3
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 316
- Enrollment target
NCT02696798 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 316 participants.
The verdict
NCT02696798, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 316 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).
Interventions
- DRUG Placebo
- DRUG Ixekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2016-04-12 |
| Est. Completion | 2019-05-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02696798
The ClinicalTrials.gov registry entry for NCT02696798 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02696798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02696798 about?
NCT02696798 is a clinical study titled "A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis". The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).
What is the current status of trial NCT02696798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 316 participants. The study started on 2016-04-12. Estimated completion is 2019-05-03.
What interventions are being tested in trial NCT02696798?
The interventions under investigation include: Placebo (DRUG), Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT02696798?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.